Sensitivity of Canine Hematological Cancers to BH3 Mimetics

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2022 Nov 26

PMID 36433867

Authors

Selvi Jegatheeson

Claire Cannon

Caroline Mansfield

Joanne Devlin

Andrew Roberts

Affiliations

Soon will be listed here.

Abstract

Background: Inhibition of antiapoptotic B-cell lymphoma 2 (BCL2) proteins by small molecule Bcl-2 homology 3 (BH3) mimetics causes rapid induction of apoptosis of human hematological cancers in vitro and in vivo.

Objectives: Assess in vitro sensitivity of non-neoplastic lymphocytes and primary hematological cancer cells from dogs to venetoclax (VEN) or the dual BCL2/ B-cell lymphoma-extra-large (BCLxL) inhibitor, navitoclax (NAV), and evaluate the association between BCL2 protein expression and VEN sensitivity.

Animals: Nine client-owned dogs without cancer and 18 client-owned dogs with hematological cancer.

Methods: Prospective, nonrandomized noncontrolled study. Lymphocytes isolated from peripheral blood, lymph node, or bone marrow from dogs were incubated with BH3 mimetics for 24 hours. Viable cells were counted using flow cytometry and half maximal effective concentration (EC ) was calculated. BCL2 protein from whole cell lysates was assessed via immunoblots.

Results: Nodal B and T lymphocytes were more sensitive to VEN than circulating lymphocytes (P = .02). Neoplastic T lymphocytes were sensitive to VEN (mean EC ± SD = 0.023 ± 0.018 μM), whereas most non-indolent B cell cancers were resistant to killing by VEN (mean EC ± SD = 288 ± 700 μM). Unclassified leukemias showed variable sensitivity to VEN (mean EC ± SD = 0.49 ± 0.66 μM). Detection of BCL2 protein was not associated with VEN sensitivity.

Conclusion And Clinical Importance: Neoplastic canine T lymphocytes are sensitive to VEN in vitro. Quantification of BCL2 protein alone is insufficient to predict sensitivity to VEN.

Citing Articles

Characterization of CD3+/CD20+ canine large-cell lymphoma.

Howard C, Anderson S, Harrington B J Vet Diagn Invest. 2023; 36(1):86-94.

PMID: 37837199 PMC: 10734595. DOI: 10.1177/10406387231204873.

Sensitivity of canine hematological cancers to BH3 mimetics.

Jegatheeson S, Cannon C, Mansfield C, Devlin J, Roberts A J Vet Intern Med. 2022; 37(1):236-246.

PMID: 36433867 PMC: 9889650. DOI: 10.1111/jvim.16587.

References

Meichner K, Fogle J, English L, Suter S . Expression of Apoptosis-regulating Proteins Bcl-2 and Bax in Lymph Node Aspirates from Dogs with Lymphoma. J Vet Intern Med. 2016; 30(3):819-26. PMC: 4913583. DOI: 10.1111/jvim.13937. View

Zhang P, Zhang X, Liu X, Khan S, Zhou D, Zheng G . PROTACs are effective in addressing the platelet toxicity associated with BCL-X inhibitors. Explor Target Antitumor Ther. 2021; 1:259-272. PMC: 8293695. DOI: 10.37349/etat.2020.00017. View

Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile T, Le Gouill S . BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2015; 30(3):761-4. PMC: 4714955. DOI: 10.1038/leu.2015.184. View

Khaw S, Merino D, Anderson M, Glaser S, Bouillet P, Roberts A . Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014; 28(6):1207-15. DOI: 10.1038/leu.2014.1. View

Jilg S, Reidel V, Muller-Thomas C, Konig J, Schauwecker J, Hockendorf U . Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2015; 30(1):112-23. DOI: 10.1038/leu.2015.179. View

Morschhauser F, Feugier P, Flinn I, Gasiorowski R, Greil R, Illes A . A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021; 137(5):600-609. PMC: 7869186. DOI: 10.1182/blood.2020006578. View

Gong J, Khong T, Segal D, Yao Y, Riffkin C, Garnier J . Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016; 128(14):1834-1844. DOI: 10.1182/blood-2016-03-704908. View

Punnoose E, Leverson J, Peale F, Boghaert E, Belmont L, Tan N . Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Mol Cancer Ther. 2016; 15(5):1132-44. DOI: 10.1158/1535-7163.MCT-15-0730. View

Tsujimoto Y, Finger L, Yunis J, Nowell P, Croce C . Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984; 226(4678):1097-9. DOI: 10.1126/science.6093263. View

10.

Adams J, Cory S . The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2017; 25(1):27-36. PMC: 5729526. DOI: 10.1038/cdd.2017.161. View

11.

Brown P, Tzannes S, Nguyen S, White J, Langova V . LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma. Vet Comp Oncol. 2017; 16(1):108-113. DOI: 10.1111/vco.12318. View

12.

OSteen S, Green D, Gopal A, Orozco J, Kenoyer A, Lin Y . Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Res. 2017; 77(14):3885-3893. PMC: 5560265. DOI: 10.1158/0008-5472.CAN-17-0082. View

13.

Phillips D, Xiao Y, Lam L, Litvinovich E, Roberts-Rapp L, Souers A . Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015; 5:e368. PMC: 4670945. DOI: 10.1038/bcj.2015.88. View

14.

Novacco M, Comazzi S, Marconato L, Cozzi M, Stefanello D, Aresu L . Prognostic factors in canine acute leukaemias: a retrospective study. Vet Comp Oncol. 2015; 14(4):409-416. DOI: 10.1111/vco.12136. View

15.

Andersson E, Putzer S, Yadav B, Dufva O, Khan S, He L . Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2017; 32(3):774-787. DOI: 10.1038/leu.2017.252. View

16.

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

17.

Zaja F, Tabanelli V, Agostinelli C, Calleri A, Chiappella A, Varettoni M . CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. Am J Hematol. 2016; 92(1):E1-E2. DOI: 10.1002/ajh.24571. View

18.

Purzycka K, Peters L, Desmas I, Davies O, Chang Y, Lara-Garcia A . Clinicopathological characteristics and prognostic factors for canine multicentric non-indolent T-cell lymphoma: 107 cases. Vet Comp Oncol. 2020; 18(4):656-663. DOI: 10.1111/vco.12589. View

19.

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

20.

Thijssen R, Diepstraten S, Moujalled D, Chew E, Flensburg C, Shi M . Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021; 137(20):2721-2735. PMC: 8138548. DOI: 10.1182/blood.2020010167. View